IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 55.173
AS - Asia 8.746
EU - Europa 6.361
SA - Sud America 1.243
AF - Africa 91
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 27
Totale 71.681
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 54.978
SG - Singapore 3.953
CN - Cina 2.004
BR - Brasile 1.041
UA - Ucraina 977
RU - Federazione Russa 939
HK - Hong Kong 858
IE - Irlanda 768
IT - Italia 728
DE - Germania 686
VN - Vietnam 636
FR - Francia 556
KR - Corea 555
PL - Polonia 422
GB - Regno Unito 397
FI - Finlandia 360
JP - Giappone 223
SE - Svezia 203
NL - Olanda 128
CA - Canada 106
IN - India 89
ID - Indonesia 70
AR - Argentina 64
BD - Bangladesh 51
MX - Messico 49
IQ - Iraq 48
ES - Italia 39
AT - Austria 35
EC - Ecuador 30
PK - Pakistan 29
AU - Australia 28
CO - Colombia 28
BE - Belgio 26
CL - Cile 26
TR - Turchia 26
PH - Filippine 24
UZ - Uzbekistan 24
MY - Malesia 23
ZA - Sudafrica 23
EG - Egitto 18
MA - Marocco 17
SA - Arabia Saudita 17
PE - Perù 16
A2 - ???statistics.table.value.countryCode.A2??? 15
IL - Israele 15
PY - Paraguay 15
TH - Thailandia 15
EU - Europa 12
GR - Grecia 12
JO - Giordania 12
NZ - Nuova Zelanda 12
PT - Portogallo 12
VE - Venezuela 12
CR - Costa Rica 9
IR - Iran 9
TW - Taiwan 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
CZ - Repubblica Ceca 7
KE - Kenya 7
LT - Lituania 7
RO - Romania 7
AL - Albania 6
AZ - Azerbaigian 6
ET - Etiopia 6
KZ - Kazakistan 6
NO - Norvegia 6
NP - Nepal 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
DZ - Algeria 5
HU - Ungheria 5
MK - Macedonia 5
PA - Panama 5
TN - Tunisia 5
UY - Uruguay 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
EE - Estonia 4
LB - Libano 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BG - Bulgaria 3
BH - Bahrain 3
GT - Guatemala 3
JM - Giamaica 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
OM - Oman 3
BS - Bahamas 2
BW - Botswana 2
CI - Costa d'Avorio 2
DM - Dominica 2
GE - Georgia 2
HR - Croazia 2
RS - Serbia 2
SV - El Salvador 2
AO - Angola 1
Totale 71.665
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.783
Wilmington 12.542
Houston 12.267
Fairfield 2.728
Singapore 1.974
Ann Arbor 1.724
Ashburn 1.493
Seattle 1.154
Chandler 910
San Jose 900
Cambridge 889
Hong Kong 849
Jacksonville 834
Dublin 687
Beijing 611
Medford 531
Dearborn 461
Hangzhou 423
Kraków 403
Santa Clara 329
New York 275
The Dalles 269
Lawrence 238
Council Bluffs 236
Ho Chi Minh City 233
Los Angeles 204
Tokyo 186
Rome 182
Lauterbourg 169
Zhengzhou 164
Hanoi 153
Helsinki 153
San Diego 137
Buffalo 135
Moscow 127
Menlo Park 120
Dallas 109
São Paulo 84
Mülheim 83
Chicago 79
Colorado Springs 74
Milan 66
Redwood City 57
Naples 56
Norwalk 55
London 52
Cardiff 47
Shanghai 47
Mountain View 46
Redondo Beach 45
Boardman 44
Jakarta 42
Monte Vista 41
Toronto 41
Detroit 40
Verona 40
Guangzhou 39
Hefei 39
San Mateo 37
Columbus 34
Nanjing 34
Rio de Janeiro 31
University Park 31
Phoenix 30
Belo Horizonte 29
Nuremberg 28
Palo Alto 28
Falls Church 27
Kunming 27
San Francisco 27
Orem 26
Brussels 25
Da Nang 25
Munich 25
Frankfurt am Main 24
Montreal 24
Brooklyn 22
Jinan 22
Saint Petersburg 22
Atlanta 21
Denver 20
Stockholm 20
Haiphong 19
Tashkent 19
Brasília 18
Redmond 17
Curitiba 16
Mexico City 16
Poplar 16
Zaltbommel 16
Manchester 15
Warsaw 15
Amsterdam 14
Baghdad 14
Chengdu 14
Chennai 14
Salvador 14
Boston 13
Biên Hòa 12
Bogotá 12
Totale 59.612
Salva come PNG Salva come JPEG
Nome #
β2-Agonist Therapy in Lung Disease 535
An update on the pharmacotherapeutic management of lower respiratory tract infections 523
A systems medicine clinical platform for understanding and managing non- communicable diseases 514
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 507
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 505
Interaction between corticosteroids and muscarinic antagonists in human airways 503
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 503
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 497
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 488
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 484
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 482
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 481
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 481
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 479
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 477
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 473
Airflow obstruction: Is it asthma or is it COPD? 473
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 473
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 473
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 469
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 466
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 463
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 461
Optimizing drug delivery in COPD: The role of inhaler devices 460
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 460
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 459
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 455
Asthma and comorbid medical illness. 454
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 453
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 449
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 445
Umeclidinium for the treatment of chronic obstructive pulmonary disease 445
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 445
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 444
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 443
Metabolic syndrome and risk of pulmonary involvement 442
The prevalence of asthma and COPD in Italy: a practice-based study 441
Tiotropium formulations and safety: a network meta-analysis 441
Asthma and comorbid medical illness 435
Bronchodilator therapy for chronic cough 434
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 431
Role of muscarinic antagonists in asthma therapy 431
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 429
The Challenges of Precision Medicine in COPD 429
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 428
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 428
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 427
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 427
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 426
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 426
New Treatments for COPD in the Elderly 423
The effect of indacaterol during an acute exacerbation of COPD 422
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 421
Translational study searching for synergy between glycopyrronium and indacaterol 419
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 419
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 418
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 418
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 417
Biomarkers of lung damage associated with tobacco smoke in induced sputum 417
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 415
Comorbidities of asthma 415
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 415
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 414
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 413
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 413
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 413
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 412
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 412
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 411
Adherence to COPD treatment: Myth and reality 411
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 408
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 405
Influence of ethnicity on response to asthma drugs 402
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 401
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 399
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 395
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 394
Indacaterol for the treatment of chronic obstructive pulmonary disease 394
Treating systemic effects of COPD 393
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 389
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 388
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 388
The clinical use of regenerative therapy in COPD 384
Cardiovascular disease in patients with COPD 382
Diabetes mellitus among outpatients with COPD attending a university hospital. 374
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 373
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 372
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 371
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 367
Biomarkers in COPD 366
Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome? 364
COPD diagnosis by a gas sensor array 363
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 362
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi 361
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 361
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 356
An update on bronchodilators in Phase I and II clinical trials 355
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 355
Brain natriuretic peptide: Much more than a biomarker 354
Dual bronchodilation and exacerbations of COPD 354
Totale 42.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 185.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 185.197
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021969 0 0 0 0 0 0 0 0 0 297 485 187
2021/20222.318 153 225 72 55 77 259 145 109 133 271 159 660
2022/20232.677 348 150 54 319 239 662 248 172 235 19 161 70
2023/2024889 192 27 68 11 85 212 61 38 16 34 12 133
2024/20255.845 217 1.349 622 318 184 206 510 321 538 548 565 467
2025/20268.824 649 503 1.208 739 889 317 1.273 1.156 1.385 705 0 0
Totale 72.366